Moreover, another study showed that a year after patients received a vascular prosthesis, adverse cardiovascular effects hospitalization due to acute myocardial infarction, cerebrovascular accident, unstable angina or revascularization developed in 32.5% of the patients who received PPIs and clopidrogel versus 21.2% among patients who received clopidrogel without PPIs. This gives a standardized incidence ratio SIR of 1.79 95% CI 1.6-1.9 33 regardless of which PPI was administered omeprazole, esomeprazole, lansoprazole or pantoprazole.
En otro estudio de pacientes con prótesis vascular, se produjeron efectos adversos cardiovasculares al año variable combinada de hospitalización por IAM, ACV, angina inestable o revascularización en el 32,5% de los que recibieron IBP y clopidogrel versus 21,2% en quienes solo recibieron clopidogrel sin IBP, dando un OR para el IBP de 1,79 IC 95% 1,6-1,9 33, independientemente de que fuera omeprazol, esomeprazol, lansonprazol o pantoprazol.